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The aim of the study was to determine the criterion validity of a computerized version of 
the General Anxiety Disorder-7 (GAD-7) questionnaire to detect general anxiety disorder 
                                                 
1
 These authors contributed the same to this work 
2
 These authors contributed the same to this work 
in Spanish primary care centers. A total of 178 patients completed the GAD-7 and were 
administered the Composite International Diagnostic Interview (CIDI) for DSM-IV Axis I 
Disorders, which was used as a reference standard. Sensitivity, specificity, positive and 
negative predictive values, and positive and negative likelihood ratios were calculated. A 
cut-off of 10 yielded a sensitivity of .87, a specificity of .78, a positive predictive value of 
.93, a negative predictive value of .64, a positive likelihood ratio of 3.96 a negative 
likelihood ratio of .17 and Younden’s Index of .65. The GAD-7 performed very well with a 
cut-off value of 10, the most frequently used cut-off point. Thus, a computerized version of 
the GAD-7 is an excellent screening tool for detecting general anxiety disorder in Spanish 
primary care settings. 
 
Keywords: screening; generalized anxiety disorder; GAD-7; primary care; criterion 
validity; computerized instruments 
 
 
1. Introduction  
Anxiety is the single most common mental disorder in Europe, affecting near 61.5 
million people (Wittchen et al., 2011). However, reported prevalence rates for this disorder 
can vary substantially across countries. According to the European Study of the 
Epidemiology of Mental Disorders (ESEMeD), which assessed 21,425 non-
institutionalized adults in six different European countries, the lifetime prevalence of any 
anxiety disorder is 13.6% and the annual prevalence is 4.2% (Alonso et al., 2004). In Spain, 
by contrast, Haro et al. (2005) assessed a general population sample of 5,473 adults, finding 
that the lifetime prevalence for any anxiety disorder was 9.4%, with a one-year prevalence 
of 5.7%. These figures are lower than those reported in the United States (US), where 
lifetime and annual prevalence rates for these disorders have been reported to be 29% and 
11%, respectively (n = 9,282) (Kessler et al., 2005). However, King et al. (2008) found no 
differences in the prevalence of anxiety disorders in the United Kingdom (UK) and Spain, 
the two countries with the highest prevalence rates in Europe. Despite the differences in 
prevalence rates among countries, there is little doubt that anxiety disorders are highly 
prevalent in Europe and more needs to be done to improve both detection and treatment.   
In Spain, as in many countries, individuals with mental disorders are often first 
identified in primary care (PC) centers. A study involving 7,936 PC patients in Spain found 
that 53.6% of the sample presented one or more mental disorders, with nearly 30% of the 
patients in that study presenting comorbidities and 11.5% suffering from concurrent 
affective, anxiety and somatoform disorders (Roca et al., 2009). Although anxiety disorders 
were only the third most common in that study (after affective and somatoform disorders), 
these still accounted for 25.6% of all mental disorders. The most common types of anxiety 
disorders were as follows: generalized anxiety disorder (GAD; 11.7%), panic disorder (PD; 
9.7%), social phobia (0.4%), and post-traumatic stress disorder (0.3%). Another study 
(Serrano-Blanco et al., 2010) recruited 3,815 patients from 77 different PC centers in Spain, 
finding a lifetime prevalence of 20.8% and an annual prevalence of 18.5% for any anxiety 
disorder. These prevalence rates are largely in line with those reported in other European 
countries (Alonso et al., 2004; Ansseau et al., 2004; Wittchen et al., 2002), and as Kessler 
et al. (2007) observed, any differences are more likely to be due to methodological issues 
rather than cultural differences.  
Of all the various types of anxiety disorders, GAD is the most common in PC 
settings (Wittchen, 2002). According to García-Campayo et al. (2012a), GAD is highly 
comorbid with other psychological disorders in PC patients in Spain (n= 2,232), as follows: 
social anxiety (37%), depression (19.1%), phobia (14%), PD (10.7%), and obsessive-
compulsive disorder (8%). Physical comorbidities are also common, including chronic pain 
(83.9%), gastrointestinal disorders (34%), cardiovascular diseases (17.3%), and diabetes 
(14%). As these findings show, GAD can have a large impact on the patient's physical 
status and, consequently, on other aspects of life. In addition, in that study, patients with 
GAD reported poor quality sleep and high sleep-onset latency, with only 16.2% of 
participants reporting restful sleep. Moreover, GAD can negatively impact quality of life 
and may lead to disability (Alonso et al., 2004; Rapaport et al., 2005), high absenteeism 
rates from work, and an increase in the use of health services. As a result, GAD is 
associated with enormous treatment-related expenses and costs associated with loss of 
productivity (Rovira et al., 2012). Like other common mental disorders in PC patients, 
anxiety disorders have become more common in Spain due to the ongoing economic crisis 
(Gili et al., 2013). Additionally, in many cases, the diagnosis of GAD in PC is incorrect or 
non-existent, with misdiagnosis rates as high as 71% (Fernández et al., 2010). For this 
reason, valid tools are needed to efficiently detect this disorder. 
The 7-item GAD scale (GAD-7) is one of the tests used in the PC setting to detect 
the presence of GAD. The GAD-7 is the anxiety module of the Patient Health 
Questionnaire (PHQ), a screening test for mental disorders in PC (Spitzer et al.,1999) that 
is used to detect and measure GAD as well as other anxiety disorders. The original PHQ 
developed by Spitzer et al. (1999) had a moderate sensitivity of .63 and a good specificity 
of .97 for any anxiety disorder (using a cut-off score of 8 points). The Spanish version of 
the PHQ includes the GAD-7 with a 3-point scale as in the original version (Diez-Quevedo 
et al., 2001), and the operating characteristics of the Spanish version also had a moderate 
sensitivity (.69) and good specificity (.99).  
In a later study (Spitzer et al., 2006), the authors developed a version of the GAD-7 
that used a 4-point scale, reporting that a cut-off score of 10 or more was the best indicator 
for anxiety disorders (sensitivity, .89; specificity, .82). García-Campayo et al. (2010) 
subsequently developed and validated the Spanish version of the GAD-7, which—unlike 
the PHQ version developed by Diez-Quevedo et al. (2001)—used a 4-point response scale, 
similar to the original English-language version of Spitzer et al. (2006). This validated 
version was found to possess excellent psychometric properties (sensitivity, .87; specificity, 
.93)—similar to the original version—using a cut-off score of 10 for diagnosis. Feasibility 
and reliability were also excellent and the scale was shown to be one-dimensional through 
factor analysis, with an explained variance of 72%. Moreover, this version of the scale has 
been validated to measure disability in Spanish PC patients with GAD (Ruiz et al., 2011).  
However, the predictive value of this scale has not yet been compared to a gold 
standard such as a clinical interview performed by a mental health professional. Indeed, 
using a computerized version of the GAD-7 in PC centers may be also useful. Given this 
context, the main aim of the present study was to study the criterion validity of a 
computerized version of the Spanish GAD-7 in a sample of PC patients in Spain who had 
been previously identified by a primary care physician (PCP) as suffering from anxiety or 
other emotional disorders.  
 
2. Method 
We studied the screening test characteristics (criterion validity) of a computerized 
version of the Spanish GAD-7 to detect anxiety disorders in users of PC services. These 
findings were then compared to the results with the Composite International Diagnostic 
Interview (CIDI), a diagnostic interview developed by the World Health Organization 
(WHO, 1990), which was used as the reference standard. 
 
2.1 Study population 
2.1.1. Setting 
The study was conducted from January 2014 to December 2014. The study sample 
included PC patients aged 18 to 65 years old. From among the 14 PC centers of the public 
health system involved in the PsicAP study (Cano-Vindel et al., 2016), we selected five 
centers from different cities of Spain (two in Valencia and one each in Albacete, Vizcaya 
and Mallorca) to recruit the sample. The ethics committees of each center, the National 
Ethics Committee, and the Spanish Agency of Medicines and Medical Devices (AEMPS), 
all approved the study protocol (code: ISRCTN58437086). These centers were selected for 
the present study because they were the first five centers approved by the ethics committee.  
 
2.1.2. Participants 
In Spain, all public health system users are assigned to a PCP who specializes in 
community and family medicine. PC is the gateway to the healthcare system for all patients 
and acts as a bridge between other services. All patients who attended PC centers with 
somatic or psychological complaints were contacted and invited to participate in the study. 
A total of 298 participants were recruited from February 2014 to December 2014 by PCPs 
from five of the 14 PC centers participating in the PsicAP Project. A total of 260 
participants voluntarily agreed to participate, gave their informed consent, and completed 
the PHQ. Thirty-eight participants were excluded for the following reasons: not reachable 
(twenty patients; 6.7%); failing to meet the age range criteria (nine patients; 3%); dropped 
out (six patients; 2%); and excluded for other reasons (three patients; 1%). Most patients 
were recruited from the two PC centers located in Valencia, with the remaining participants 
recruited from the centers in Albacete, Mallorca, and Vizcaya. After all the patients 
completed the PHQ and other registration procedures, they were asked to participate in the 
sub-study. Then, the CIDI was administered by trained psychologists to the 178 
participants who voluntarily agreed to take this test. Socio-demographic variables for the 
entire sample and for the subset of participants who completed the CIDI interview were 
similar (as indicated by t-tests or chi-squared tests, depending on variable type; all p ≥.35). 
Among the five participating PC centers, the dropout rate was slightly higher at the center 
in Vizcaya (p < .05). Table 1 shows the socio-demographic variables and medications 
administered. 
 
2.2. Measurement instruments 
2.2.1. Patient Health Questionnaire (PHQ).  
The PHQ is a self-report screening test derived from the PRIME-MD test (Spitzer et 
al., 1999). It is a two-stage system, containing the Patient Questionnaire and the Physicians’ 
Clinical Evaluation Guide, used to evaluate mental disorders in the PC setting. The PHQ 
includes modules to assess somatization (PHQ-15), depressive disorder (PHQ-9), PD 
(PHQ-PD), GAD (GAD-7), eating disorders and alcohol-related disorders.  
 
2.2.2. Generalized Anxiety Disorder-7 (GAD-7).  
The PHQ includes the GAD-7 (items 5a-5g of the questionnaire). This module is 
used to screen for the GAD symptoms described in the DSM-IV, as follows: (5a) jitters; 
(5b) excessive restlessness; (5c) fatigue; (5d) muscular pain or tension; (5e) sleeping 
problems; (5f) attention problems and (5g) easy irritability. The Spanish version of the 
PHQ (Diez-Quevedo, 2001) includes a 3-point response scale ranging from 0 (“not at all”) 
to 1 (“several days”) and 2 (“more than half the days”) and requires an algorithm for GAD 
with a response of “more than half the days” on item 5a and also on three or more of items 
5b-g. As in the original English (Spitzer et al., 2006), the Spanish version of the GAD- 7 
validated by García-Campayo et al. (2010) includes a 4-point response scale ranging from 0 
(“never”) to 1 (“several days”), 2 (“more than half the days”) and 3 (“nearly every day”), 
providing a total score that ranges from 0 to 21. According to Spitzer et al. (2006), the total 
score can be classified into four degrees of severity: minimum (0-4), mild (5-9), moderate 
(10-14) and severe (15-21). The validated Spanish version (García-Campayo et al., 2010) 
uses the same classification system, which thus differs slightly from the original PHQ. 
Using a cut-off of 10 points, the reported sensitivity and specificity of the original English 
version is .89 and .82, respectively, whereas the corresponding values on the Spanish 
version validated by García-Campayo et al. (2010) are .86 and .93, respectively. In the 
present study, we used this latest version (García-Campayo et al., 2010) rather than the 
older GAD-7 version included in the PHQ (Diez-Quevedo et al., 2001).   
 
2.2.3. Composite International Diagnostic Interview (CIDI).  
The CIDI is a structured interview for psychiatric disorders following the DSM-IV 
(APA, 2000) and CIE-10 (WHO, 1990) criteria. The GAD module of the CIDI (Spanish 
version) was used for diagnosis (WHO, 1997). 
 
2.3 Procedure 
Patients with anxious, depressive or physical symptoms without a clear biological 
basis were invited to participate in the study by their PCP. All participants completed the 
Patient Information Sheet and provided informed consent. Once signed, a new meeting was 
arranged during which patients were again provided with details about the study; during 
this same meeting, the participants completed a computerized version of the PHQ and other 
measurement instruments. A dedicated personal computer was brought to the PC 
consultation and connected wirelessly to internet. Participants were then instructed to 
connect to the study website to take the test, which had been previously programmed to 
collect all data in computerized form. Participants completed all the PHQ and GAD-7 items 
by clicking on answers on screen. All items for each sub-module of the PHQ and the GAD-
7 appeared together on the screen. Participants were permitted to correct their answers if 
they so desired. If any item was not answered, the program providing a warning, reminding 
participants to complete all items as they were required to answer all of the questions. 
Next, participants were scheduled to take the CIDI. All participants received the 
Patient Information Sheet and after signing the informed consent, were interviewed by a 
trained psychologist who was blinded to the GAD-7 results. All psychologists (7 in total) 
that performed the clinical interviews were trained by a senior clinical psychologist through 
online sessions.  
 
2.4. Statistical analysis 
To obtain the criterion validity of the GAD-7, a ROC curve analysis was performed: 
the following values were calculated based on the scoring criteria: sensitivity (which 
measures the proportion of positive results correctly identified as such), specificity (which 
measures the proportion of negative results correctly identified as such), positive and 
negative predictive values (the proportions of positive and negative test results  that are, 
respectively, true positive and true negative results), and positive and negative likelihood 
ratios (used to assess the value of performing the diagnostic test). The internal consistency 
of the GAD-7 was assessed with Cronbach’s  and  McDonald’s ω, both of which showed 
satisfactory indexes in the current sample (Cronbach’s  = 83; McDonald’s ω = .84). The 
optimal cut-off value (defined as a balance between sensitivity and specificity) was 
identified as the value corresponding to the maximum value of Youden’s index, calculated 
as (sensitivity + specificity– 1).  
3. Results 
3.1 PHQ results 
As Table 2 shows, of the 260 patients that completed the PHQ, a large proportion (n 
= 203; 78%) were diagnosed with major depressive disorder (MDD) according to PHQ-9 
criteria (scores ≥ 10) and the DSM-IV diagnostic algorithm (n = 178; 68%). Approximately 
half of all patients (n = 141; 54%) were diagnosed with somatization disorder (SD) (PHQ-
15 ≥ 5) and more than two-thirds (n = 180; 69%) were diagnosed with GAD (GAD-7 ≥ 10). 
In addition, comorbidity among disorders was high (n = 150; 58%), particularly between 
GAD and MDD; in addition, nearly half of patients (n = 117; 45%) with GAD had 
comorbid SD, while a similar proportion (n = 104; 40%) presented concurrent GAD, SD 
and MDD (see Table 2). 
 
 
3.2. Diagnosis using CIDI 
When the prevalence of GAD was measured with the CIDI GAD module, one 
hundred and thirty-seven (77%) of the 178 patients had a positive diagnosis. Thirty-six 
patients (20.2%) were diagnosed with concurrent GAD, MDD and PD, one hundred and 
thirteen patients (63.5%) were diagnosed with MDD alone, and forty-six patients (25.8%) 
with PD alone. 
 
3.3. Operating characteristics of GAD-7 as a screening test 
A ROC curve analysis of the GAD-7 showed that the test performed well, with an 
area under the curve of .86 (Figure 1). A cut-off of 10 yielded the best test characteristics 
for GAD: sensitivity, .87; specificity, .74; positive and negative predictive values of .93 and 
.64, respectively; and positive and negative likelihood ratios of 3.96 and .17, respectively. 
This cut-off also yielded the best Younden’s index (J = .65). Of the patients with a GAD 
CIDI diagnosis, 86% had a score ≥ 10, while 78% of patients without a GAD diagnosis 
scored below this cut-off value. The discriminating statistics for different possible cut-off 
values are shown in Table 3.    
   
 
4. Discussion 
The results reported here support the value of a computerized version of the 
validated Spanish version of the GAD-7 as a diagnostic tool for GAD among patients at 
Spanish PC centers. The screening test characteristics were consistent with those described 
previously by Spitzer et al. (2006) and García-Campayo et al. (2010). Unlike the validation 
of the Spanish version of the GAD-7, our results are supported by a clinical interview as a 
gold standard, which is the major strength of our study.  
In line with Spitzer et al., (2006), both the sensitivity (.87) and specificity (.74) were 
high when a cut-off score of 10 was used. Compared to the GAD-7 version by García-
Campayo et al. (2010), we found an identical sensitivity but a lower specificity. By 
contrast, the older Spanish version of the GAD-7 (Diez-Quevedo et al., 2001), had a lower 
sensitivity (.69) but higher specificity (.99). Moreover, our results were better than the 
initial results reported by Spitzer et al. (1999) when the PHQ anxiety disorder module was 
first developed; in that study, the sensitivity was only .63 although the specificity was .97. 
Nevertheless, it is plausible that these differences may be explained by the non-comparable 
samples. For example, the original Spanish version of the GAD-7 by Diez-Quevedo et al. 
(2001) was conducted in a sample of hospital inpatients. By contrast, our sample consisted 
of PC patients. Yet, our results validate the utility of the GAD-7 in the PC setting.   
At a cut-off score of 10, the positive predictive value was quite high, indicating that 
only 7% of positive cases would not be detected in our sample of patients with emotional 
disorders. This finding is similar to that reported by García-Campayo et al. (2010) but 
better than values reported by Spitzer et al. (2006), who found a positive predictive value of 
only 29%. Nevertheless, we found a low negative predictive value, indicating that 36% of 
GAD cases would not be detected correctly; as a result, the number of false-positives was 
high. Overall, our results demonstrate that the GAD-7 is highly sensitive with a high 
predictive value for positive cases but is limited in terms of its specificity and negative 
predictive value. In general, we found that a high prevalence of GAD (nearly 72%) among 
the patients evaluated in our sample, a finding that was expected given that the PCPs 
referred these patients to our clinical trial after medical diagnosis.  
When comparing the confusion matrix to the gold standard interview, the specificity 
is the same (.78) for cut-off scores of 10 and 11, with nine false-positive cases and thirty-
two true negative cases. Sensitivity was better at a cut-off score of 10 (one hundred 
nineteen true positive cases and eighteen false negative cases) compared to a cut-off of 
eleven (one hundred and four true positives and thirty-three false negatives). These data 
support the decision to select the cut-off score of 10 as the most appropriate cut-off point. 
Moreover, the Youden’s index with this cut-off score was .65, confirming that this cut point 
offers a better balance between sensitivity and specificity.   
The number of false-negatives in our sample was relatively low, leading us to 
conclude that the GAD-7 has a good sensitivity with a high predictive value. However, 
there were a large number of false-positives given that the PHQ did not confirm the CIDI 
diagnosis of GAD in many cases. This finding means that the specificity was only 
moderate, which can be explained by the fact that our sample was taken from PCP referrals 
of patients suffering from several emotional disorders (such as anxiety, depression or 
somatization). In addition, comorbidity was highly prevalent in our sample, although 
patients without GAD diagnoses may also report anxiety symptoms. Thus, any self report 
used in this context will show low specificity. Notwithstanding the moderate specificity, 
this study of the GAD-7 in this PC sample offers ecological validity for PC settings, which 
is important given the time constraints and scarcity of resources in this setting, as well as 
the high prevalence of several comorbid conditions, both mental and physical. Thus, the use 
of the GAD-7 may be helpful to detect GAD in this setting due its high sensitivity.    
The positive likelihood ratio found in this work suggests that the test works very 
well for GAD: the disorder was detected in approximately 4 patients for every patient 
without the disorder (4:1). The negative likelihood ratio was even better, with negative 
cases detected 6 times more often in healthy patients than in GAD patients (6:1).       
To improve the detection and diagnosis of GAD in Spanish PC centers, the PCP 
could use the GAD-7 or the GAD-2, an ultra-short version of the GAD-2 containing only 
the two central items from the GAD-7 and which has also been found to have appropriate 
psychometric properties (García-Campayo et al., 2012b). If the GAD-2 is positive, then the 
GAD-7 could be administered to confirm the diagnosis. However, although our results 
indicate that the GAD-7—given its high sensitivity and positive predictive values—is a 
reliable and relatively accurate test for detecting GAD, the test still yields a large number of 
false positives (due to its low specificity and negative predictive value). For this reason, 
other measures should be performed to confirm the GAD-7 diagnosis and to rule out 
potential false positives. Thus, when necessary, this test could be followed by the full PHQ 
(Diez-Quevedo et al., 2001) to more accurately assess the presence of GAD with 
comorbidities. The next diagnostic step could involve administration of the CIDI GAD 
module by a clinical psychologist to make a final diagnosis and to refer the patient to the 
appropriate psychological treatment at the PC center or a specialized treatment center.  
 
Study limitations 
As described above, participants completed a computerized version of the self-
report measures. The use of an electronic questionnaire requires participants to be familiar 
with the use of a computer, and this is potentially an additional barrier for the correct 
administration of this test, especially in older people, particularly given that elderly people 
have been reported to have difficulties in understanding the GAD-7 (García-Campayo et 
al., 2010). In addition, considering the large number of false positives, it is possible that 
some participants exaggerated their answers, which could have affected the specificity of 
the GAD-7 results. Another possible limitation is that PC service users are often a highly 
heterogeneous group and the sample size was not large. However, this potential limitation 
may have been minimized by the fact that a criterion standard diagnostic interview for 
anxiety was used to ensure the reliability of our results.  
 
Conclusions 
This is the first time that the criterion validity of the Spanish version of the GAD-7 
(computerized) has been compared to a clinical interview used as a gold standard. Our 
results show that this computerized version of the GAD-7 is a highly valuable tool for 
diagnosing GAD among patients at Spanish PC centers. The screening test characteristics 
were good and largely consistent with previous reports. We conclude that the GAD-7 can 
be used with confidence as an initial screening tool at PC centers due to its strong 
ecological validity. However, given the large number of false-positives, the diagnosis 
should be confirmed by other instruments—including the full PHQ and/or the CIDI GAD 
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Table 1. Demographics  
  
Total sample 
(n = 260) 
 
CIDI completed 





Primary Care Center 
   
 
    Albacete 39 15.0 
 
21 11.8 
   Mallorca 33 12.7 
 
30 16.9 
   Valencia 155 59.6 
 
122 68.5 




   
 
    Female 186 71.5 
 
125 70.2 




   
 
    Married 130 50.0 
 
86 48.3 
   Divorced 28 10.8 
 
21 11.8 
   Widowed 5 1.9 
 
3 1.7 
   Separated 19 7.3 
 
14 7.9 
   Never married 48 18.5 
 
29 16.3 
   Unmarried  30 11.5 
 
25 14.0 
Level of education 
   
 
    No schooling 7 2.7 
 
4 2.2 
   Basic education 94 36.2 
 
71 39.9 
   Secondary education 40 15.4 
 
27 15.2 
   High School 64 24.6 
 
46 25.8 
   Bachelor 47 18.1 
 
27 15.2 




   
 
    Part-time employee 28 10.8 
 
18 10.1 
   Employed full time 85 32.7 
 
58 32.6 
   Unemployed, in search of work 77 29.6 
 
52 29.2 
   Unemployed, not looking for work 36 13.8 
 
27 15.2 
   Temporary low labor 14 5.4 
 
11 6.2 
   Permanent low labor 4 1.5 
 
2 1.1 




   
 
    Less than 12,000 euros 119 45.8 
 
87 48.9 
   12,000 euros to 24,000 euros 112 43.1 
 
79 44.4 
   Between 24,000 euros and 36,000 euros 20 7.7 
 
10 5.6 






   
 
 
Table 2. PHQ diagnoses and comorbidity 
  
Total sample 
(n = 260) 
 
CIDI completed 





Somatoform disorder (SD)     
    D (≤ 5) 141 54.2 
 
94 52.8 
Major depressive disorder (MDD) 
   
 
    MDD (Algorithm) 178 68.5 
 
124 69.7 





   
 










General anxiety disorder (GAD)  
   
 




   
 




   
 




   
 
    MDD + GAD  150 57.7 107 60.1 
   MDD + SD 115 44.2  81 45.5 
   GAD + SD 117 45.0  81 45.5 
   MDD + GAD + SD 104 40.0  74 41.6 
   GAD + PD 45 17.3  33 18.5 
   MDD + PD 40 15.4  30 16.9 
   MDD + GAD + PD 37 14.2  29 16.3 
   PD + SD 42 16.2  27 15.2 
   SD + GAD + PD 36 13.8  25 14.0 
   MDD + SD + PD 34 13.1  23 12.9 
   SD + MDD + PD + GAD 32 12.3  22 12.4 
   SD + MDD + PD + GAD  
   + Eating + Alcohol 
1 0.4  1 0.3 
Note. SD = somatoform disorder, MDD = major depressive disorder, PD = panic disorder, GAD = general 
anxiety disorder, Eating = eating disorder, Alcohol = alcohol abuse. Comorbidity categories are not exclusive 
(e.g., “MDD + GAD” comprises “MDD + GAD +  D”). 
*
 riginal Algorithm: All of the first four questions are answered with “yes,” and presence of four or more 
somatic symptoms during an anxiety attack 
+
Modified Algorithm: At least two of the first four questions are answered with “yes,” other coding criteria 
unchanged. (see Muñoz-Navarro et al., 2016) 
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Highlights 
 Generalized anxiety disorder is highly prevalent in Spanish primary care centers. 
 The criterion validity was tested of a computerized version of the Spanish GAD-7.   
 The GAD-7 performed very well as a screening instrument with a cut-off of 10. 
 A ROC curve study was compared to the CIDI clinical interview as a gold standard. 
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